VOL: 101, ISSUE: 49, PAGE NO: 33
GENERIC AND PROPRIETARY NAMES
- Inhibits the first and second phase of ADP-induced effects in platelet aggregation.
- Antiplatelet drugs.
- Prevention of ischaemic events in symptomatic ischaemic disease.
- In combination with low-dose aspirin in acute coronary syndrome without ST elevation.
- Active bleeding.
- Avoid in first few days post-myocardial infarction and for seven days post-stroke.
- Increased risk of bleeding.
- Liver or renal impairment.
- Gastrointestinal problems.
- Bleeding disorders.
- Taste disturbance.
- Blood disorders.
- Hypersensitivity-like reactions.
- Increased bleeding tendency with anticoagulants, aspirin, nonsteroidal anti-inflammatory medication, coumarins, phenindione dipyridamole and iloprost.
- Administer with food to reduce gastric symptoms.
- Discontinue medication seven days before elective surgery if antiplatelet effect is not desirable.
- The combination of low-dose aspirin and clopidogrel in acute coronary syndrome without ST elevation is given for at least one month but no longer than 9-12 months. The routine long-term use of this combination increases the risk of bleeding without clear evidence of benefits.
- Ensure that patients are aware of the importance of informing health care professionals, including doctors and dentists, that they are taking clopidogrel before starting any other treatment.
- Advise patients that excessive intake of alcohol should be avoided with this medication.
- Ensure that patients know they should report any signs of increased bleeding and bruising.
- Nurses should refer to manufacturer’s summary of product characteristics and to appropriate local guidelines